

Application No:10/507,272; Docket No: 10500-008  
Amdt. dated January 20, 2006  
Reply to Office action of October 20, 2005

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-15 (cancelled).

16. (previously presented) A method of use of type 1 Placental Growth Factor (PLGF-1) comprising preparing a medicament that comprises PLGF-1 as an active principle, wherein said medicament promotes angiogenesis in the treatment of a state selected from the group consisting of:

- diseases and pathological alterations involving the cutaneous or subcutaneous connective tissue,
- scleroderma, and
- early skin aging due to exposure to atmospheric aggressive agents or to protracted solar irradiation.

17. (previously presented) The method of use according to claim 16, wherein the state is selected from the group consisting of localized scleroderma and progressive systemic scleroderma.

18. (previously presented) The method of use according to claim 17, wherein the localized scleroderma is cutaneous scleroderma and the progressive systemic scleroderma is myocardial scleroderma.

19. (previously presented) The method of use according to claim 16, for treatment of a pathological loss of hair due to a state selected from the group consisting of alopecia, hormonal disorders, chemotherapy, radiotherapy and administration of medicine.

Application No:10/507,272; Docket No: 10500-008  
Amdt. dated January 20, 2006  
Reply to Office action of October 20, 2005

20. (previously presented) The method of use according to claim 16, wherein the medicament is in a form suitable for generating a local or systemic effect.

21. (previously presented) The method of use according to claim 16, wherein the medicament is in a form suitable for endovenous, intramuscular, intrarticular, subcutaneous or topical administration or subcutaneous implant or ionophoresis.

22. (previously presented) The method of use according to claim 19, wherein the medicament is in a form suitable for endovenous, intramuscular, intrarticular, subcutaneous or topical administration or subcutaneous implant or ionophoresis.

23. (previously presented) A method of use of type 1 Placental Growth Factor (PLGF-1) comprising administering to adult individuals PLGF-1 to promote cutaneous or subcutaneous angiogenesis in the prevention and cosmetic treatment of natural skin aging.

24. (previously presented) A method of use of type 1 Placental Growth Factor (PLGF-1) comprising administering to adult individuals PLGF-1 to promote perifollicular angiogenesis in the prevention and in the cosmetic treatment of the natural loss of hair.

25. (previously presented) The method of use according to claim 23, wherein the PLGF-1 is formulated in a cosmetic composition for topical administration.

26. (previously presented) The method of use according to claim 24, wherein the PLGF-1 is formulated in a cosmetic composition for topical administration.

27. (previously presented) The method of use according to claim 16, wherein PLGF-1 is comprised in an amount suitable for an administration of 1 to 500  $\mu\text{g}$  per Kg of body per day, preferably of 10  $\mu\text{g}/\text{Kg}/\text{day}$  to 200  $\mu\text{g}/\text{Kg}/\text{day}$ .

Application No:10/507,272; Docket No: 10500-008  
Amdt. dated January 20, 2006  
Reply to Office action of October 20, 2005

28. (previously presented) The method of use according to claim 23, wherein PLGF-1 is comprised in an amount suitable for an administration of 1 to 500  $\mu\text{g}$  per Kg of body per day, preferably of 10  $\mu\text{g}/\text{Kg}/\text{day}$  to 200  $\mu\text{g}/\text{Kg}/\text{day}$ .

29. (previously presented) The method of use according to claim 24, wherein PLGF-1 is comprised in an amount suitable for an administration of 1 to 500  $\mu\text{g}$  per Kg of body per day, preferably of 10  $\mu\text{g}/\text{Kg}/\text{day}$  to 200  $\mu\text{g}/\text{Kg}/\text{day}$ .

30. (currently amended) A pharmaceutical composition comprising type 1 Placental Growth Factor (PLGF-1) as active principle and a pharmaceutically acceptable excipient, wherein at least 98.5% of the PLGF-1 is in active dimeric and multimeric form, at least 70% is in dimeric form and no more than 1.5% is in monomeric form, and wherein PLGF-1 is comprised in an amount from 50  $\mu\text{g}$  to 30 mg per unitary dose for parenteral use and in an amount from 0.1 mg to 10 mg per gram of said pharmaceutical composition for topical use.

31. (currently amended) A cosmetic composition comprising type 1 Placental Growth Factor (PLGF-1) as active principle and a cosmetically acceptable excipient, wherein at least 98.5% of the PLGF-1 is in active dimeric and multimeric form, at least 70% is in dimeric form and no more than 1.5% is in monomeric form, and wherein PLGF-1 is comprised in an amount from 0.01 mg to 0.09 mg per gram of said cosmetic composition.

32. (previously presented) The composition according to claim 30, in a form selected from the group consisting of a solution, a lotion, a W/O emulsion, an O/W emulsion, a suspension, a liposome suspension, a gel, a cream, a paste, an ointment and a subcutaneous implant.

33. (previously presented) The composition according to claim 31, in a form selected from the group consisting of a solution, a lotion, a W/O emulsion, an O/W emulsion, a suspension, a liposome suspension, a gel, a cream, a paste, an ointment and a subcutaneous implant.

Application No:10/507,272; Docket No: 10500-008

Amdt. dated January 20, 2006

Reply to Office action of October 20, 2005

34. (previously presented) The composition according to claim 30, additionally comprising one or more substances capable of stabilizing the PLGF-1 in the active dimeric-multimeric forms.

35. (previously presented) The composition according to claim 31, additionally comprising one or more substances capable of stabilizing the PLGF-1 in the active dimeric-multimeric forms.